Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Clinical trial NCT03742895 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03742895
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-12
- Primary completion
- 2025-08-12
- Enrollment
- 329
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.